IDXX · Idexx Laboratories Inc /De
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. IDEXX reported Q2 2026 revenue up 10% reported/9% organic and raised full-year revenue and EPS guidance while advancing incremental growth investments, though U.S. same-store clinical visits declined 1.3% in the quarter with continued pressure on wellness visits.
- + Raised full-year 2026 revenue outlook to $4,700M-$4,745M and EPS to $14.69-$14.94, with organic revenue growth outlook raised ~40 bps at midpoint to 8.5%-9.7%
- + Q2 organic revenue grew 9% with CAG Diagnostics recurring revenue up 10.3% organically, including nearly 12% international growth
- + Q2 comparable operating margin expanded 110 basis points and EPS grew 15% on a comparable basis to $4.27
- + Raised full-year free cash flow conversion outlook to 90%-100% of net income
- + IDEX InView DX installed base surpasses 9,000 instruments with over 1,600 placements in Q2, on pace for 5,500 full-year placement goal
- + Strong growth in Water (13% organic) and LPD (9% organic) plus record sixth straight quarter of DR50+ digital radiography placements
- − U.S. same-store clinical visits declined 1.3% in Q2, with continued pressure on wellness visits (down ~3.4% per Reference Lab commentary)
- − Updated FX assumptions created a $15 million headwind to 2026 reported revenue outlook and a $0.05 EPS headwind
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IDXX
this stock
Idexx Laboratories Inc /De
|
$40.91B | -22.8% | +10.4% | 36.5 | 2.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +16.5% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -3.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.4% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IDXX | +0.0% | -4.2% | -10.7% | -6.2% | -22.8% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +0.7% | -4.3% | -22.9% | -5.6% | -34.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.